ReviewMolecular biotechnology2003
Therapeutic inhibition of angiogenesis.
Review in Molecular biotechnology, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Evaluation of a xenogeneic VEGF vaccine in dogs with soft tissue sarcoma.Cancer immunology, immunotherapy : CII · 2007Article
- Alphastatin downregulates vascular endothelial cells sphingosine kinase activity and suppresses tumor growth in nude mice bearing human gastric cancer xenografts.World journal of gastroenterology · 2006Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Angiogenesis, or the growth of new blood vessels, has, in recent years, become an area of intense scientific research. The primary reason for this has been the realization that angiogenesis plays a key role in many common pathologies, and that its inhibition could have profound implications in the treatment of these disorders. A substantial number of anti-angiogenic agents have now been identified; however, none has, as of yet, achieved widespread acceptance in the clinic. Many agents have been identified as the result of clearly defined research programs, such as the inhibitors of the vascular endothelial growth factor transmembrane tyrosine kinase receptors, but many other simply by screening. The purpose of this article is to review the wealth of information available on known anti-angiogenic agents and to assess their future potential.
Indexed as
Identifiers
14526126What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.